Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Sarah M. Larson, Umar Farooq, Boyu Hu, Tahir Latif, Felix A. Mensah, Deepthi Kolli, Giulia Parisi, Greg P. Kaufman, Jonathan E. Benjamin, Akil Merchant

Blood (2024) 144 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2024-200697

Published: 2024

Journal Articles

A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Sarah M. Larson, Yvonne Y Chen, Jim Johnston, Sylvain Roy, Pinakin Patel, Jonathan E Benjamin

Blood (2023) 142 (Supplement 1): 6892.

https://doi.org/10.1182/blood-2023-187614

Published: 2023

Journal Articles

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

Blood (2018) 131 (14): 1522–1531.

https://doi.org/10.1182/blood-2017-08-798322

Published: 2018

Includes: Supplemental data

Journal Articles

Assessment of Tumor Depletion Following Tandem Mobilization in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

David B. Miklos, Aaron C. Logan, Christine E. Ryan, Kelsi Schoenrock, Maria Garcia, Mark Klinger, Katherine A Kong, Malek Faham, Rob Negrin, Jonathan E. Benjamin

Blood (2014) 124 (21): 2010.

https://doi.org/10.1182/blood.V124.21.2010.2010

Published: 2014

Journal Articles

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Wen-Kai Weng, MD PhD, Randall Armstrong, Sally Arai, MD, Laura Johnston, MD, Ginna G. Laport, MD, Robert Lowsky, MD, David B. Miklos, Judith A. Shizuru, MD PhD, Jonathan E. Benjamin, Robert S. Negrin, MD, Sunil Reddy, MD, Lynn Million, MD, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2014) 124 (21): 2544.

https://doi.org/10.1182/blood.V124.21.2544.2544

Published: 2014

Journal Articles

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Sally Arai, Bita Sahaf, Balasubramanian Narasimhan, George L. Chen, Carol D. Jones, Robert Lowsky, Judith A. Shizuru, Laura J. Johnston, Ginna G. Laport, Wen-Kai Weng, Jonathan E. Benjamin, Joanna Schaenman, Janice Brown, Jessica Ramirez, James L. Zehnder, Robert S. Negrin, David B. Miklos

Blood (2012) 119 (25): 6145–6154.

https://doi.org/10.1182/blood-2011-12-395970

Published: 2012

Includes: Supplemental data

Journal Articles

Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies

Jonathan E. Benjamin, MD, PhD, Ginna G. Laport, MD, Laura J. Johnston, MD, Sally Arai, MD, Wen-Kai Weng, MD, PhD, Judith A. Shizuru, MD, PhD, David B. Miklos, MD, PhD, Ruby M. Wong, PhD, Linda V. Elder, Karl G. Blume, MD, Robert S. Negrin, MD, Robert Lowsky, MD

Blood (2008) 112 (11): 4383.

https://doi.org/10.1182/blood.V112.11.4383.4383

Published: 2008

NARROW

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Assessment of Tumor Depletion Following Tandem Mobilization in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Assessment of Tumor Depletion Following Tandem Mobilization in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence

Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only